Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase

Leukemia

Volumn 27, Issue 11, 2013, Pages 2254-2256

  Metzgeroth, G ^a   Schwaab, J ^a   Gosenca, D ^a   Fabarius, A ^a   Haferlach, C ^b   Hochhaus, A ^c   Cross, N C P ^d,e   Hofmann, W K ^a   Reiter, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD; BONE MARROW; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CYTOGENETICS; EOSINOPHILIA; EOSINOPHILIA ASSOCIATED MYELOID NEOPLASM; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FUSION GENE; GENE; GRANULOCYTIC SARCOMA; HEART; HUMAN; LETTER; LONG TERM CARE; LUNG; LYMPH NODE; LYMPHOBLAST; LYMPHOMA; MYELOID LEUKEMIA; MYOCARDITIS; OVERALL SURVIVAL; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN; SPLENOMEGALY; T LYMPHOCYTE;

EID: 84887318253     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.129     Document Type: Letter

References (12)

1. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481-487. (Pubitemid 34879335)
2. Bain BJ. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica 2010; 95: 696-698.
3. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214. (Pubitemid 36359296)
4. Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92: 1173-1179. (Pubitemid 350144174)
5. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABLnegative chronic myeloproliferative disorders. Blood 2007; 109: 61-64. (Pubitemid 46053044)
6. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22: 1999-2010.
7. Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A et al. Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRalphapositive chronic eosinophilic leukaemia. Cancer Chemother Pharmacol 2011; 67: 967-969.
8. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008; 143: 707-715.
9. Pardanani A, D'Souza A, Knudson RA, Hanson CA, Ketterling RP, Tefferi A. Longterm follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. Leukemia 2012; 26: 2439-2441.
10. Erben P, Gosenca D, Mü ller MC, Reinhard J, Score J, Del Valle F et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 2010; 95: 738-744.
11. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia- associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007; 21: 1183-1188. (Pubitemid 46831806)
12. Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 2008; 119: 199-206.